Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Treating Depression in Clinical Practice: New Insights on the Multidisciplinary Use of Tradozone

Umberto Albert
ORCID logo ,
Carmine Tomasetti
* ORCID logo ,
Camillo Marra
,
Francesca Neviani
,
Alessandro Pirani
,
Daiana Taddeo
,
Orazio Zanetti
,
Giuseppe Maina
ORCID logo
Version 1 : Received: 21 February 2023 / Approved: 22 February 2023 / Online: 22 February 2023 (08:42:51 CET)

How to cite: Albert, U.; Tomasetti, C.; Marra, C.; Neviani, F.; Pirani, A.; Taddeo, D.; Zanetti, O.; Maina, G. Treating Depression in Clinical Practice: New Insights on the Multidisciplinary Use of Tradozone. Preprints 2023, 2023020380. https://doi.org/10.20944/preprints202302.0380.v1 Albert, U.; Tomasetti, C.; Marra, C.; Neviani, F.; Pirani, A.; Taddeo, D.; Zanetti, O.; Maina, G. Treating Depression in Clinical Practice: New Insights on the Multidisciplinary Use of Tradozone. Preprints 2023, 2023020380. https://doi.org/10.20944/preprints202302.0380.v1

Abstract

Depression is estimated to be a leading contributor to the global mental health-related burden. The determinants of this huge prevalence lie in the fact that depressive symptoms may be comorbid in a wide variety of disorders, thus complicating and exacerbating their clinical pictures. This makes the treatment of depressive symptoms even more difficult since many pharmacological and pharmacokinetic interactions should be considered by physicians approaching the therapy. Hence, depression still represents a challenge for both psychiatrists and the other clinicians, in terms of its high rates of relapse and resistance despite well-established protocols. It is also complicated by the well-known latency in its complete response to current antidepressant treatments. In this context, the search for new strategies in antidepressant treatment is mandatory; even including revising the use of “old” pharmacotherapies by considering their specific features may help to perfecting the treatment of depression, both in its standalone psychiatric manifestation and in the framework of other clinical conditions. The results of a consensus of experts regarding the possible use of trazodone as a valuable strategy for addressing the “real world” unmet needs of depression treatment is herein reported. This is based on the unique characteristics of this drug possibly delivering a rapid antidepressant action as compared to other selective serotonin reuptake inhibitors (SSRIs) as well as on its pharmacodynamic malleability and pharmacokinetic tolerability when used in the milieu of other drugs in treating comorbid depressive symptoms.

Keywords

serotonin antagonist/reuptake inhibitors; comorbidity; psychiatric disorders; neurological disorders; dementia; primary care

Subject

Medicine and Pharmacology, Psychiatry and Mental Health

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.